<DOC>
	<DOCNO>NCT00984178</DOCNO>
	<brief_summary>The aim study compare effectiveness four different strategy prevent ventricular postinfarction remodelling : 1 ) Conventional treatment reperfunded extensive acute myocardial infarction , 2 ) Autologous bone marrow stem-cells intracoronary transplantation 3 ) mobilization bone marrow stem-cells induced granulocyte colony-stimulating factor ( G-CSF ) ; 4 ) combine treatment ( stem-cells transplantation plus mobilization G-CSF ) .</brief_summary>
	<brief_title>Trial Hematopoietic Stem Cells Acute Myocardial Infarction</brief_title>
	<detailed_description>This clinical study phase II randomize trial patient acute extensive reperfunded myocardial infarction undergo coronary artery revascularization sirolimus coat stent . The aim study compare effectiveness four different strategy prevent ventricular postinfarction remodelling : 1 ) Conventional treatment reperfunded extensive acute myocardial infarction , 2 ) Autologous bone marrow stem-cells intracoronary transplantation 3 ) mobilization bone marrow stem-cells induced granulocyte colony-stimulating factor ( G-CSF ) ; 4 ) combine treatment ( stem-cells transplantation plus mobilization G-CSF ) . The investigational follow-up 30 day , 4 9 months.Effectiveness therapy neomyogenesis measure Magnetic Resonance Imaging analysis leave ventricular size global regional function myocardial viability.The impact therapy stent re-endothelialization restenosis analyse angiography intracoronary ultrasound 30 day 9 month . The impact different treatment neoangiogenesis measure infarct relate artery intracoronary study evolution coronary flow reserve . Also , measure haematopoietic precursor kinetic different treatment branch .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<criteria>Age 18 75 year Acute myocardial infarction follow characteristic : Clinical symptom chest pain last &gt; 30 minute , unresponsive nitroglycerin . Typical myocardial enzymatical necrotic curve Total sum STsegment elevation â‰¥ 6 mm 12lead electrocardiogram . Akynesis hypokinesis infarctrelated artery area without contractility abnormality rest area . Pharmacological , mechanical type reperfusions ( facilitate angioplasty ) evidence normal infarcted area epicardial flow ( TIMI grade 3 ) first 24 hour begin symptom Successful repair infarctrelated artery ( residual poststenting stenosis &lt; 30 % visual estimation epicardial normal flow [ grade 3 ] first 24 hour begin symptom lack significant residual lesion evidence ( &lt; 50 % visual estimation ) infarctrelated artery . Lack evidence significant lesion remain coronary vessel adequate revascularization achieve first 24 hour symptom begin . The presence cardiogenic shock define sustain systolic blood pressure le 90 mm Hg , response fluid systolic blood pressure le 100 mm Hg vasopressor ( absence bradycardia ) Suspicion evidence infarct mechanical complication History sustain ventricular tachycardia atrial fibrillation Patient cardiac defibrillator candidate potential implantation . Investigational drug treatment previous 4 week Actual potential use antineoplastic drug Oncology antecedent last 5 year Previous treatment trans myocardial laser revascularization Women childbearing potential Severe concomitant disease modify patient 's survival study Inability suspend thrombolytic treatment Active bleeding major surgery within 2 week forbid use heparin , abciximab antiplatelet therapy . Previous malignant haematology disease ( leukaemia lymphoma ) hypercoagulability disorder ( antiphospholipid syndrome , antithrombin , Cprotein Sprotein V Leiden Factor deficiency ) Previous know renal failure ( creatinine &gt; 2.5 mg /dl ) Any kind stroke last year whenever episode haemorrhagic stroke . Major surgery pending next year Previously know vascular disease prevents catheterization . Evidence hypersensitivity Filgrastim , proteins derive E. coli formulation component . Inability give write informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Reperfusion</keyword>
	<keyword>acute myocardial infarction</keyword>
	<keyword>stem cell therapy</keyword>
	<keyword>GCSF</keyword>
	<keyword>bone marrow mononuclear cell</keyword>
	<keyword>magnetic resonance</keyword>
</DOC>